
    
      The study population will include at least 100 consecutive subjects 6-17 years of age with
      suspected contact dermatitis based on symptoms and clinical history. Study subjects must be
      otherwise healthy and fulfill entry criteria.

      Visit 1 (Day 0): Informed Consent, Inclusion/Exclusion Criteria Assessment, Medical and
      Medicine History, Pregnancy Test (for female subjects of child-bearing potential), Panel
      Placement.Visit 2 (Day 2): Panel Removal, Panel Adhesion and Irritation Assessment, AE and
      Concomitant Medication Review.Visit 3 (Day 3- approximately 72 hours after placement): Skin
      Reactions Assessed and Scored. Adverse Event and Concomitant Medication Review.Visit 4 (Day 4
      approximately 96 hours after placement): Skin Reactions Assessed and Scored. Adverse Event
      and Concomitant Medication Review.Visit 5 (Day 7±1): Skin Reaction Assessed and Scored. AE
      and Concomitant Medication Review. Visit 6 (Day 21±2): Skin Reaction Assessed and Scored. AE
      and Concomitant Medication Review. Visit performed via phone call, unless investigator
      determines that subject should be seen in clinic.

      Primary Endpoint: Frequency and characterization of positive reactions per allergen.
      Secondary Endpoint: Prevalence of late or persistent reactions, irritation, adhesion,
      subject-reported itching or burning, and adverse events.
    
  